ST. PAUL,
Minn., May 29, 2024 /PRNewswire/ -- ScaleReady,
in collaboration with Wilson Wolf Manufacturing, Bio-Techne
Corporation (NASDAQ: TECH) and CellReady, today announced the
launch of the G-Rex® Grant Program, a $20
million initiative to propel the advancement of cell and
gene therapies (CGT).
The G-Rex® Grant Program will provide academic
and commercial institutions engaged in IND enabling pre-clinical
research, process development, and/or ongoing GMP
manufacturing of cell and gene therapies with the material
resources and services needed to implement or optimize a highly
efficient G-Rex® based cell manufacturing platform. Qualifying
programs can receive up to $300,000
in G-Rex® devices, critical reagents, capital equipment,
application support, and manufacturing consultation services.
"Wilson Wolf is
eager to participate in the G-Rex® Grant Program," said
John Wilson, CEO of Wilson Wolf
Manufacturing. "G-Rex® is used in nearly 50% of CGT clinical trials
and four commercially approved T cell therapies. We hope everyone
using G-Rex®, or considering G-Rex®, will take advantage of our
extensive cell therapy manufacturing expertise. Time and money are
the two most important things in short supply in this field and we
can help fix that. When allowed to review batch records, we have a
proven history of saving many months and millions of dollars while
simultaneously increasing yield and potency."
"The G-Rex® Grant Program is a transformative
initiative that will significantly reduce the barrier to entry for
CGT institutions who seek access to our industry leading G-Rex®
platform," said Josh Ludwig, Global
Commercial Director at ScaleReady. "Time is the most valuable
resource we all have. G-Rex® is the only integrated development and
manufacturing platform in the world that provides continuity
between the research, development, and manufacturing functions.
G-Rex® platform continuity saves valuable time by ensuring that
critical process parameters (CPPs) and critical quality attributes
(CQAs) are conserved during the translation or troubleshooting
process. By equipping researchers and developers with the
best-in-class tools and expertise they need, we can accelerate the
development and improve the manufacturability of these
potentially lifesaving treatments."
"Bio-Techne is committed to providing researchers
with the tools they need to develop groundbreaking therapies," said
Will Geist, President of
Bio-Techne's Protein Sciences Segment. "The G-Rex® Grant Program
aligns perfectly with this mission by supporting the development of
cell and gene therapies that have the potential to revolutionize
healthcare."
G-Rex® Grants will be awarded to applicants that
provide a compelling overview of why a G-Rex® Grant would be
beneficial, a strong willingness to work collaboratively to achieve
program goals, a demonstrated track record of successful program
management, and a provision of well understood deliverables.
The application process is designed to be simple
and facilitate a collaborative discussion to refine potential
program goals. By participating, recipients can expect faster and
more cost-effective development timelines, a smoother transition
from research labs to GMP manufacturing, and a stronger data
package for IND applications. Ultimately, the program aims to
expedite clinical data generation, reduce the complexity of the
development process, increase the manufacturability, throughput and
scalability of existing or future CGT programs, and increase
patient access to these potentially lifesaving therapies.
Interested parties can learn more by following
this link to initiate the G-Rex® Grant Program.
About ScaleReady
ScaleReady is a
center of excellence that is bringing the future of cell
and gene therapies to life with its powerful and
versatile manufacturing platform and extensive array of
collaborative CGT experts. Founded in 2020, ScaleReady is
a joint venture of Bio-Techne, Fresenius Kabi,
and Wilson Wolf that brings together tools and
technologies for cell culture, cell activation, gene
editing, and cell processing from each founding partner. Learn more
at www.scaleready.com.
About Wilson Wolf
Manufacturing
Wilson Wolf
(www.wilsonwolf.com) is dedicated to simplifying cell and
gene-modified cell (CGT) therapy research, process development, and
manufacturing. This is being accomplished through its scalable
G-Rex® technology, which is used throughout the world in CGT
applications ranging from basic research to commercial drug
production.
Wilson Wolf's
mission is to create hope for cancer patients, one G-Rex® device at
a time.
About Bio-Techne Corporation
Bio-Techne
Corporation (NASDAQ: TECH) is a global life sciences company
providing innovative tools and bioactive reagents for the research
and clinical diagnostic communities. Bio-Techne, in partnership
with Wilson Wolf, is creating
products such as media and cytokines that are specifically tailored
to G-Rex® Bioreactors, including right sized reagent quantities in
containers that are tailored to high throughput closed system
manufacturing. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the
Company on social media
at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David
Clair, Vice President, Investor Relations & Corporate
Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the
world's first and only G-Rex® centric contract development and
manufacturing organization (CDMO) specializing in G-Rex® based cell
and gene-modified cell therapy development and manufacturing. The
company offers a wide range of services to support the development
and commercialization of these therapies.
CellReady's mission is to create hope for cancer
patients, one G-Rex® process at a time.
For more information about the G-Rex® Grant
Program, please contact:
info@scaleready.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-20-million-g-rex-grant-program-for-the-advancement-of-cell-and-gene-therapy-cgt-development-and-manufacturing-302157494.html
SOURCE Bio-Techne Corporation